Oral vaccination with inactivated influenza vaccine induces cross-protective immunity

Vaccine

Volumn 30, Issue 2, 2012, Pages 180-188

  Quan, Fu Shi ^a,b   Compans, Richard W ^b   Kang, Sang Moo ^b,c  

^a Chungju National University   (South Korea)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Cross protection; Influenza; Oral vaccination

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VAGINA;

EID: 84355161915     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.028     Document Type: Article

References (35)

1. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(April (1)):68-89.
2. Mitragotri S. Immunization without needles. Nat Rev 2005, 5(December (12)):905-916.
3. Bergmann K.C., Waldman R.H., Tischner H., Pohl W.D. Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine. Int Arch Allergy Appl Immunol 1986, 80(1):107-109.
4. Avtushenko S.S., Sorokin E.M., Zoschenkova N.Y., Zacharova N.G., Naichin A.N. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization. J Biotechnol 1996, 44(January (1-3)):21-28.
5. Moldoveanu Z., Novak M., Huang W.Q., Gilley R.M., Staas J.K., Schafer D., et al. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 1993, 167(January (1)):84-90.
6. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(January (1)):1-15.
7. Lazzell V., Waldman R.H., Rose C., Khakoo R., Jacknowitz A., Howard S. Immunization against influenza in humans using an oral enteric-coated killed virus vaccine. J Biol Stand 1984, 12(July (3)):315-321.
8. Barackman J.D., Ott G., Pine S., O'Hagan D.T. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin Diagn Lab Immunol 2001, 8(May (3)):652-657.
9. Lu X., Clements J.D., Katz J.M. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 2002, 20(January (7-8)):1019-1029.
10. Katz J.M., Lu X., Young S.A., Galphin J.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis 1997, 175(February (2)):352-363.
11. Meitin C.A., Bender B.S., Small P.A. Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci U S A 1994, 91(November (23)):11187-11191.
12. Conacher M., Alexander J., Brewer J.M. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001, 19(April (20-22)):2965-2974.
13. Mann J.F., Shakir E., Carter K.C., Mullen A.B., Alexander J., Ferro V.A. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 2009, 27(June (27)):3643-3649.
14. Pang G.T., Clancy R.L., O'Reilly S.E., Cripps A.W. A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunization. J Virol 1992, 66(February (2)):1162-1170.
15. Quan F.S., Compans R.W., Nguyen H.H., Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008, 82(February (3)):1350-1359.
16. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007, 81(April (7)):3514-3524.
17. Quan F.S., Yoo D.G., Song J.M., Clements J.D., Compans R.W., Kang S.M. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol 2009, 83(May (9)):4489-4497.
18. Slifka M.K., Ahmed R. Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J Immunol Methods 1996, 199(November (1)):37-46.
19. Amorij J.P., Westra T.A., Hinrichs W.L., Huckriede A., Frijlink H.W. Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 2007, 26(December (1)):67-76.
20. Strid J., Callard R., Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology 2006, 119(September (1)):27-35.
21. Nagao K., Ginhoux F., Leitner W.W., Motegi S., Bennett C.L., Clausen B.E., et al. Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc Natl Acad Sci U S A 2009, 106(March (9)):3312-3317.
22. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(May (19)):3871-3878.
23. Quan F.S., Kim Y.C., Yoo D.G., Compans R.W., Prausnitz M.R., Kang S.M. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One 2009, 4(9):e7152.
24. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405(September (1)):165-175.
25. Chang S.Y., Kweon M.N. Langerin-expressing dendritic cells in gut-associated lymphoid tissues. Immunol Rev 2010, 234(March (1)):233-246.
26. Wiersbitzky S., Bruns R., Seidel E., Tischner H., Broda J., Gocht A., et al. Clinical and immunologic effects following oral immunization against influenza in children in day care and infection susceptible young children. Padiatr Grenzgeb 1990, 29(1):43-51.
27. Petrilli F.L., Crovari P., Cuneo-Crovari P., Badolati G., Canepa R. Oral influenza vaccination with live attenuated viruses. 1. Acceptability, immunogenicity and transmissibility. B I Sieroter Milan 1975, 54(October (4)):312-322.
28. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75(June (11)):5141-5150.
29. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003, 21(July (23)):3212-3218.
30. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83(June (11)):5726-5734.
31. Gluck R., Mischler R., Durrer P., Furer E., Lang A.B., Herzog C., et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 2000, 181(March (3)):1129-1132.
32. Gluck R. Review of intranasal influenza vaccine. Adv Drug Deliv Rev 2001, 51(September (1-3)):203-211.
33. Petrilli F.L., Crovari P., Cuneo-Crovari P., Badolati G., Canepa R. Oral influenza vaccination with live attenuated viruses. 2. Protective efficacy during a type A(H3N2) epidemic. B I Sieroter Milan 1975, 54(October (4)):323-330.
34. Mann J.F., Ferro V.A., Mullen A.B., Tetley L., Mullen M., Carter K.C., et al. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine 2004, 22(June (19)):2425-2429.
35. Prabakaran M., Madhan S., Prabhu N., Qiang J., Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 2010, 84(April (7)):3201-3209.